Research
Hormonal
AOM therapy requires monitoring and potential dose reduction of concomitant medications for diabetes and hypertension due to rapid weight loss and improved metabolic parameters.
If you take medication for diabetes or high blood pressure, tell your doctor you are starting an AOM. Your doses may need to be lowered quickly as you lose weight to prevent dangerous drops in blood sugar or blood pressure.
GoodSupportsHIGH confidence
With significant weight loss, dose reductions are often needed for antidiabetic medications, antihypertensives, and diuretics... In some cases, proactive dose adjustments of these concomitant medications may be considered early in the course of AOM therapy to reduce the risk of hypoglycemia... or hypotension.
Why this rating
Based on clinical trial observations and standard care guidelines.
Source
Nutritional considerations with antiobesity medications
Jaime P. Almandoz et al. · Obesity · 2024
DOI 10.1002/oby.24067
narrative_reviewCited 104×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Antiobesity medications (AOMs) such as semaglutide and tirzepatide significantly reduce energy intake and appetite, necessitating a shift in nutritional focus from caloric restriction alone to ensuring nutrient density and adequate protein intake to prevent lean mass loss and deficiencies.Good
- Adequate dietary protein intake (60-75 g/day or up to 1.5 g/kg body weight/day) is critical during AOM therapy to preserve lean body mass and prevent complications like weakness and edema, especially in older adults.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →